Vitamin D3 for Life

Live Enlightened

Research libraryVitamin D3 For Life
Study design and methods

Secondary relevance to vitamin D This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.

This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.

Why this paper is included

Supporting source evidence:

Risedronate treatment led to increased serum levels of bone-formation markers (e.g., osteocalcin, PTH, and vitamin D; Supplementary Fig.

Source: Risedronate led to abnormal cortical bone remodeling in femurs but not in lumbar cortical bones. View original paper

Relevance classification does not establish study quality, causation or editorial approval.

Study design Study design awaiting verification.

Study design awaiting verification

The available source does not establish a sufficiently clear study design.

Meta-analysis unclear · Blinding unclear / not reported · Animal research reported

How this paper was classified

Automatic source-based classification; awaiting editorial verification. This is not a quality score.

The mice were given ad libitum access to a standard rodent chow diet and normal tap water.

Source: Methods.

View supporting evidence in the original paper

What the study types mean
Systematic review
Uses explicit methods to identify, assess and summarise research on a defined question.
Scoping review
Maps the extent and characteristics of research on a topic.
Narrative review
Discusses existing research; systematic-review methods have not been established by this classification.
Review / evidence synthesis
Reviews existing research; the exact review methods need further assessment.
Randomised controlled trial
Assigns participants or groups to comparison interventions by chance.
Non-randomised intervention study
Examines an intervention without random allocation.
Cohort study
Examines exposures and outcomes over time within a defined group.
Case-control study
Compares people with an outcome against people without it, examining exposures.
Cross-sectional study
Examines a population at a particular point in time.
Observational study
Observes exposures and outcomes without assigning the exposure; the subtype is not established here.
Case report
Describes an individual case.
Case series
Describes a group of individual cases.
Secondary analysis
Analyses existing study data; this paper is not automatically another independent trial.
Laboratory study
Investigates biological processes in a laboratory setting.
Qualitative study
Examines experiences or meanings using qualitative methods.
Genetic instrumental-variable study
Uses genetic variation as an instrument to investigate relationships; this is not a randomised treatment trial.
Study protocol
Describes planned methods and is not evidence that the planned study has reported results.
Multiple reported designs
More than one design is explicitly reported; examine the supporting methods.
Study design awaiting verification
The available source does not establish a sufficiently clear study design.

Meta-analysis combines numerical results from studies. Blinding describes who was unaware of treatment allocation. Neither is a separate quality grade. Study design, vitamin D relevance and document format are independent filters.

Abstracts

Metabolic activities affect femur and lumbar vertebrae remodeling, and anti-resorptive risedronate disturbs femoral cortical bone remodeling

Study design awaiting verification · Experimental & Molecular Medicine · 2021

Original publication title

Metabolic activities affect femur and lumbar vertebrae remodeling, and anti-resorptive risedronate disturbs femoral cortical bone remodeling

Mi Yeong Kim; Kyunghee Lee; Hong-In Shin; Kyung-Jae Lee; Daewon Jeong

© The Author(s) 2021

Original publication · Publisher record · CC BY 4.0

Source wording retained. Formatting, section navigation and display-title punctuation adapted for this research record.

At a glance

What does the authors’ abstract report?

Metabolic activities are closely correlated with bone remodeling and long-term anti-resorptive bisphosphonate treatment frequently causes atypical femoral fractures through unclear mechanisms. To explore whether metabolic alterations affect bone remodeling in femurs and lumbar vertebrae and whether anti-osteoporotic bisphosphonates perturb their reconstruction, we studied three mouse strains with different fat and lean body masses (BALB/c, C57BL6, and C3H mice). These mice displayed variable physical activity, food and drink intake, energy expenditure, and respiratory quotients. Following intraperitoneal calcein injection, double calcein labeling of the femoral diaphysis, as well as serum levels of the bone-formation marker procollagen type-I N-terminal propeptide and the bone-resorption marker C-terminal telopeptide of type-I collagen, revealed increased bone turnover in mice in the following order: C3H > BALB/c ≥ C57BL6 mice.

In addition, bone reconstitution in femurs was distinct from that in lumbar vertebrae in both healthy control and estrogen-deficient osteoporotic mice with metabolic perturbation, particularly in terms of femoral trabecular and cortical bone remodeling in CH3 mice. Interestingly, subcutaneous administration of bisphosphonate risedronate to C3H mice with normal femoral bone density led to enlarged femoral cortical bones with a low bone mineral density, resulting in bone fragility; however, this phenomenon was not observed in mice with ovariectomy-induced femoral cortical bone loss.

Together, these results suggest that diverse metabolic activities support various forms of bone remodeling and that femur remodeling differs from lumbar vertebra remodeling. Moreover, our findings imply that the adverse effect of bisphosphonate agents on femoral cortical bone remodeling should be considered when prescribing them to osteoporotic patients.

Osteoporosis: Metabolic links to femur fragility

The metabolic status of post-menopausal women may influence their susceptibility to osteoporosis and their risk of femur fractures when taking anti-osteoporosis drugs. Metabolic activity influences bone density and turnover, particularly following estrogen loss after menopause. Long-term osteoporosis treatment with bisphosphate drugs causes femur fractures in some patients, but the reasons for this are unclear. Kyung-Jae Lee at Keimyung University, Daewon Jeong at Yeungnam University, both in Daegu, South Korea, and co-workers studied three mice strains with phenotypes showing different fat and lean-body masses and found distinct variations between femur and lumbar vertebrae remodeling, with femur remodeling more readily affected by metabolic activity.

Both control and estrogen-deficient mice with high levels of body fat exhibited abnormal femur remodeling. Treatment with bisphosphates caused femur fragility in control mice in this group, but not in the estrogen-deficient mice.

Authors’ abstract

Metabolic activities are closely correlated with bone remodeling and long-term anti-resorptive bisphosphonate treatment frequently causes atypical femoral fractures through unclear mechanisms. To explore whether metabolic alterations affect bone remodeling in femurs and lumbar vertebrae and whether anti-osteoporotic bisphosphonates perturb their reconstruction, we studied three mouse strains with different fat and lean body masses (BALB/c, C57BL6, and C3H mice). These mice displayed variable physical activity, food and drink intake, energy expenditure, and respiratory quotients. Following intraperitoneal calcein injection, double calcein labeling of the femoral diaphysis, as well as serum levels of the bone-formation marker procollagen type-I N-terminal propeptide and the bone-resorption marker C-terminal telopeptide of type-I collagen, revealed increased bone turnover in mice in the following order: C3H > BALB/c ≥ C57BL6 mice.

In addition, bone reconstitution in femurs was distinct from that in lumbar vertebrae in both healthy control and estrogen-deficient osteoporotic mice with metabolic perturbation, particularly in terms of femoral trabecular and cortical bone remodeling in CH3 mice. Interestingly, subcutaneous administration of bisphosphonate risedronate to C3H mice with normal femoral bone density led to enlarged femoral cortical bones with a low bone mineral density, resulting in bone fragility; however, this phenomenon was not observed in mice with ovariectomy-induced femoral cortical bone loss.

Together, these results suggest that diverse metabolic activities support various forms of bone remodeling and that femur remodeling differs from lumbar vertebra remodeling. Moreover, our findings imply that the adverse effect of bisphosphonate agents on femoral cortical bone remodeling should be considered when prescribing them to osteoporotic patients.

Osteoporosis: Metabolic links to femur fragility

The metabolic status of post-menopausal women may influence their susceptibility to osteoporosis and their risk of femur fractures when taking anti-osteoporosis drugs. Metabolic activity influences bone density and turnover, particularly following estrogen loss after menopause. Long-term osteoporosis treatment with bisphosphate drugs causes femur fractures in some patients, but the reasons for this are unclear. Kyung-Jae Lee at Keimyung University, Daewon Jeong at Yeungnam University, both in Daegu, South Korea, and co-workers studied three mice strains with phenotypes showing different fat and lean-body masses and found distinct variations between femur and lumbar vertebrae remodeling, with femur remodeling more readily affected by metabolic activity.

Both control and estrogen-deficient mice with high levels of body fat exhibited abnormal femur remodeling. Treatment with bisphosphates caused femur fragility in control mice in this group, but not in the estrogen-deficient mice.

Publication and source details

Original title: Metabolic activities affect femur and lumbar vertebrae remodeling, and anti-resorptive risedronate disturbs femoral cortical bone remodeling

Mi Yeong Kim; Kyunghee Lee; Hong-In Shin; Kyung-Jae Lee; Daewon Jeong

Experimental & Molecular Medicine · 2021

© The Author(s) 2021https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.https://doi.org/10.13039/501100003725National Research Foundation of Korea (NRF)2015R1A5A20091242016R1A2B2012108Jeong Daewon

Repository JATS snapshot; version as supplied

Source retrieved: 2026-11-12T13:37:56.953103+00:00

DOI: 10.1038/s12276-020-00548-w · PMC8080628